AstraZeneca and Daiichi Sankyo Win First U.S. Approval for Novel Breast Cancer Treatment; Stock Rises Most in Five Months

Jan 19, 2025, 05:37 PM

AstraZeneca and Daiichi Sankyo have received U.S. approval for a novel breast cancer treatment, marking a significant milestone in their efforts to establish the drug as a widely used option in oncology. This approval represents the first authorization for this closely monitored treatment, which has prompted a notable increase in Daiichi Sankyo's stock, rising the most in five months. The approval was confirmed by multiple sources, including the FDA and various news outlets.